The FDA cleared four notable therapies within the same week in late August, spanning infectious disease, cardiometabolic care ...
This article explores strategies for formulating complex and emerging biologics, the role of predictive modeling, and ...
In December 2025, FDA announced that it was deploying agentic AI capabilities across the agency. FDA defined these systems as ...
FDA approves Rasonque (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer, validating RAS ...
Continuous direct compression can provide a simplified alternative pathway for selected spray-dried dispersion formulations ...
Pharma industry experts indicate that strategy in 2026 is shifting to agentic AI, sustainable efficiency, and resilient supply chains to manage tariffs, regulations, and digitalization. To formulate a ...
In part 2 of his overview on hold times in biopharmaceuticals, Robert Dream details the regulations that govern hold times ...
On August 19,2026, the FDA accepted Teva Pharmaceuticals' New Drug Application (NDA) for ecopipam, an investigational ...
David S. Thompson, CSAP, is Chief Alliance Officer at Eli Lilly and Company.
McKesson plans to absorb Precision Medicine Group into Oncology & Multispecialty, adding CRO, lab, biomarker, market access, and commercialization capabilities to its existing healthcare services ...
A dual delivery capsule platform provides delivery of multiple APIs with a single dosage unit, which reduces pill burden and simplifies dosing regimens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results